mirvetuximab soravtansine
What is the most important information I should know about mirvetuximab soravtansine?
Call your doctor at once if you have any eye problems, including blurred vision, eye pain, or new or worsening vision problems.
What is mirvetuximab soravtansine?
Mirvetuximab soravtansine is used to treat adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are no longer responding to platinum-based chemotherapy and have received 1 to 3 types of chemotherapy.
Your doctor will perform a tests to make sure mirvetuximab soravtansine is the right treatment for you.
Mirvetuximab soravtansine may also be used for purposes not listed in this medication guide.
What should I discuss with my healthcare provider before receiving mirvetuximab soravtansine?
Tell your doctor if you have or have ever had:
- vision or eye problems; or
- liver problems.
May harm an unborn baby. Do not use if you are pregnant. Use effective birth control while using mirvetuximab soravtansine and for at least 7 months after your last dose. Tell your doctor if you become pregnant.
You may need to have a negative pregnancy test before starting this treatment.
Do not breastfeed while using this medicine, and for at least 1 month after your last dose.
How is mirvetuximab soravtansine given?
Follow all directions on your prescription label and read all medication guides or instruction sheets.
Your doctor may change, delay, or permanently discontinue your treatment with mirvetuximab soravtansine if you have certain side effects.
Mirvetuximab soravtansine is usually given every 3 weeks as an infusion into your vein. Your doctor will decide how many cycles you need.
You may be given other medications to help prevent serious side effects or allergic reaction. Keep taking these medicines for as long as your doctor has prescribed.
You may need frequent vision exams.
Your doctor may prescribe eye drops before and during your treatment with mirvetuximab soravtansine. You should use these eye drops as directed by your doctor.
What happens if I miss a dose?
Call your doctor for instructions if you miss an appointment for your mirvetuximab soravtansine injection.
What should I avoid while receiving mirvetuximab soravtansine?
Avoid wearing contact lenses while using mirvetuximab soravtansine unless your doctor tells you to.
What are the possible side effects of mirvetuximab soravtansine?
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
- dry eyes, sensitivity to light, blurred vision, eye pain, or new or worsening vision changes;
- cough, chest pain, trouble breathing, shortness of breath; or
- numbness, tingling, or burning pain in your hands or feet.
Common side effects may include:
- abnormal lab results;
- nausea, stomach pain, diarrhea, constipation;
- fever, mouth sores, skin sores, sore throat, cough; or
- pale skin, tiredness, feeling light-headed or short of breath, cold hands and feet.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect mirvetuximab soravtansine?
Tell your doctor about all your current medicines. Many drugs can affect mirvetuximab soravtansine, especially:
- nefazodone;
- cancer medicine --ceritinib, idelalisib, ribociclib, tucatinib;
- an antibiotic --clarithromycin, telithromycin;
- antifungal medicine --itraconazole, ketoconazole, posaconazole, voriconazole; or
- antiviral medicine for HIV or hepatitis C --boceprevir, cobicistat, dasabuvir, elvitegravir, indinavir, lopinavir/ritonavir, nelfinavir, ombitasvir, paritaprevir saquinavir, telaprevir, tipranavir.
This list is not complete and many other drugs may affect mirvetuximab soravtansine. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.
Where can I get more information?
Your doctor or pharmacist can provide more information about mirvetuximab soravtansine.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2023 Cerner Multum, Inc. Version: 1.03. Revision date: 3/3/2023.
This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content.